Search This Blog

Wednesday, October 5, 2016

New Amgen Data In Melanoma And Metastatic Colorectal Cancer To Be Presented At The European Society For Medical Oncology 2016 Congress

Interim Data From Phase 2 Trial Provides Further Insight Into IMLYGIC® (Talimogene Laherparepvec) as a Potential Combination Partner With a Checkpoint Inhibitor for Patients With Advanced Melanoma
Retrospective Analyses of Key Studies Evaluating Vectibix® (Panitumumab) Combination Regimen in First- and Second-Line Metastatic Colorectal Cancer Evaluate Impact of Tumor Site of Origin on Treatment Efficacy

Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.